Clinical Trial Update: PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant [EARLY_Phase 1]

View source ↗

Summary

This update reports the completion of an early-phase trial assessing preemptive rituximab to prevent recurrence of focal segmental glomerulosclerosis after kidn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University of Minnesota | Conditions: Focal Segmental Glomerulosclerosis | EARLY_Phase 1 | Status: COMPLETED